Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umeclidinium
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as maintenance treatment for chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It works by blocking acetylcholine at muscarinic receptors in the airways, leading to bronchodilation and improved airflow. Umeclidinium is administered via oral inhalation once daily and does not relieve acute COPD attacks.
- Brand names
- Incruse Ellipta
- Other names
- 乌体林斯
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM3 (M3)CHRM5 (M5)CHRM2 (M2)CHRM4 (M4)
Beyond the preview
Go deeper on umeclidinium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umeclidinium.